ArticleUrology2016
Combined Biparametric Prostate Magnetic Resonance Imaging and Prostate-specific Antigen in the Detection of Prostate Cancer: A Validation Study in a Biopsy-naive Patient Population.
Article in Urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Diagnostic Performance of Prostate-specific Antigen Density for Detecting Clinically Significant Prostate Cancer in the Era of Magnetic Resonance Imaging: A Systematic Review and Meta-analysis.European urology oncology · 2024Pooled it
- A systematic review and meta-analysis of the diagnostic accuracy of biparametric prostate MRI for prostate cancer in men at risk.Prostate cancer and prostatic diseases · 2021Pooled it
- Accuracy of multiparametric magnetic resonance imaging for diagnosing prostate Cancer: a systematic review and meta-analysis.BMC cancer · 2019Pooled it
- A predictive model based on biparametric magnetic resonance imaging and clinical parameters for improved risk assessment and selection of biopsy-naïve men for prostate biopsies.Prostate cancer and prostatic diseases · 2019Trial
- The use of biparametric magnetic resonance imaging in active surveillance of prostate cancer.BJUI compass · 2026Article
- A Report on the Use of Biparametric MRI in Prostate Cancer Diagnosis: A Two-Year Single Centre Experience.Cureus · 2025Article
- Ultra-high gradient performance 3-Tesla MRI for super-fast and high-quality prostate imaging: initial experience.Insights into imaging · 2024Article
- Reduction of false positives using zone-specific prostate-specific antigen density for prostate MRI-based biopsy decision strategies.European radiology · 2024Article
- Biparametric versus multiparametric MRI for the detection of clinically significant prostate cancer in a diverse, multiethnic population.Abdominal radiology (New York) · 2024Article
- Dynamic Contrast-Enhanced Study in the mpMRI of the Prostate-Unnecessary or Underutilised? A Narrative Review.Diagnostics (Basel, Switzerland) · 2023Review
- Deep learning algorithm performs similarly to radiologists in the assessment of prostate volume on MRI.European radiology · 2023Article
- Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy.World journal of urology · 2022Article
- Early experience in avoiding biopsies for biopsy-naïve men with clinical suspicion of prostate cancer but non-suspicious biparametric magnetic resonance imaging results and prostate-specific antigen density < 0.15 ng/mLActa radiologica open · 2022Article
- Is perfect the enemy of good? Weighing the evidence for biparametric MRI in prostate cancer.The British journal of radiology · 2022Review
- PMP(Porphyrin-Micelle-PSMA) Nanoparticles for Photoacoustic and Ultrasound Signal Amplification in Mouse Prostate Cancer Xenografts.Pharmaceutics · 2021Article
- Role of MRI for the detection of prostate cancer.World journal of urology · 2021Review
- Biparametric versus multiparametric magnetic resonance imaging of the prostate: detection of clinically significant cancer in a perfect match group.Prostate international · 2020Article
- How Fast Can We Go: Abbreviated Prostate MR Protocols.Current urology reports · 2020Review
- Necessity of differentiating small (< 10 mm) and large (≥ 10 mm) PI-RADS 4.World journal of urology · 2020Article
- Is dynamic contrast enhancement still necessary in multiparametric magnetic resonance for diagnosis of prostate cancer: a systematic review and meta-analysis.Translational andrology and urology · 2020Article
Corrections and comments
- Commented on by
- Commented on byAuthor Reply.2016
- Commented on by
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo validate the use of biparametric (T2- and diffusion-weighted) magnetic resonance imaging (B-MRI) and prostate-specific antigen (PSA) or PSA density (PSAD) in a biopsy-naive cohort at risk for prostate cancer (PCa).
methodsAll patients (n = 59) underwent PSA screening and digital rectal exam prior to a B-MRI followed by MRI or transrectal ultrasound fusion-guided targeted biopsy. Previously reported composite formulas incorporating screen positive lesions (SPL) on B-MRI and PSA or PSAD were developed to maximize PCa detection. For PSA, a patient was considered screen positive if PSA level + 6 × (the number of SPL) >14. For PSAD, screening was positive if PSAD × 14 + (the number of SPL) >4.25. These schemes were employed in this new test set to validate the initial formulas. Performance assessment of these formulas was determined for all cancer detection and for tumors with Gleason ≥3 + 4.
resultsScreen positive lesions on B-MRI had the highest sensitivity (95.5%) and negative predictive value of 71.4% compared with PSA and PSAD. B-MRI significantly improved sensitivity (43.2-72.7%, P = .0002) when combined with PSAD. The negative predictive value of PSA increased with B-MRI, achieving 91.7% for B-MRI and PSA for Gleason ≥3 + 4. Overall accuracies of the composite equations were 81.4% (B-MRI and PSA) and 78.0% (B-MRI and PSAD).
conclusionValidation with a biopsy-naive cohort demonstrates the parameter SPL performed better than PSA or PSAD alone in accurately detecting PCa. The combined use of B-MRI, PSA, and PSAD resulted in improved accuracy for detecting clinically significant PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.